GLP-1 Weight-Loss Pills May Strain Employer Health Plans

The launch of new GLP-1 weight-loss pills by pharmaceutical giants Novo Nordisk and Eli Lilly is anticipated to increase demand for these medications. However, this surge in demand may pose challenges for employees relying on employer-sponsored health insurance to cover the costs.
Employer-sponsored health plans are already grappling with rising costs associated with GLP-1 medications, with annual per-participant expenses frequently exceeding $10,000 to $15,000. Nationally, GLP-1 drugs now account for approximately 14% of all U.S. prescription drug spending, escalating from $13.7 billion in 2018 to $132 billion by early 2026.
Coverage for GLP-1 medications varies significantly among employers. According to the 2025 KFF Employer Health Benefits Survey, nearly 20% of large employers cover these drugs for weight loss, with coverage increasing to 43% among firms with 5,000 or more employees. However, some employers are reconsidering this coverage due to cost pressures. Surveys indicate that 10% of employers currently offering GLP-1 coverage plan to drop it in 2027.
Expanding coverage for GLP-1 medications could lead to higher insurance premiums. The Employee Benefit Research Institute (EBRI) estimates that broadening coverage could increase premiums by up to 14%, depending on eligibility and adherence scenarios.